Baricitinib is an oral medication that belongs to a class of drugs known as Janus kinase (JAK) inhibitors. It works by blocking the activity of one or more of the Janus kinase family of enzymes, which play a key role in the process of inflammation and immune system activity. It is primarily approved for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to other therapies.
